Unlock instant, AI-driven research and patent intelligence for your innovation.

Novel arabinosyladenine derivatives

A technology of sugar adenine and derivatives, which is applied in the field of 2-substituted arabinose adenine derivatives, can solve the problems such as the inability to obtain strong antiviral effect and the inability to meet the requirements of ADA resistance.

Inactive Publication Date: 2004-04-21
NIPPON ZOKI PHARM CO LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

According to the experimental results of the present inventors, as figure 1 As shown, the introduction of lower alkyl groups such as methyl and ethyl groups at the 2-position of Ara-A cannot obtain a strong antiviral effect
In addition, these compounds also fall short in terms of resistance to ADA

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel arabinosyladenine derivatives
  • Novel arabinosyladenine derivatives
  • Novel arabinosyladenine derivatives

Examples

Experimental program
Comparison scheme
Effect test

reference example 1

[0072] Synthesis of 9-(β-D-arabinofuranoyl)-2-methyladenine [comparison compound A]

[0073] Dissolve 1 gram of AICN arabinoside and 2 milliliters of acetonitrile in 50 milliliters of ammonia-saturated methanol at 0°C, and heat in an autoclave at 140°C for 16 hours. After the reaction, the solvent was distilled off, and the residue was purified by silica gel column separation and recrystallized with distilled water to obtain the reference compound (745 mg) as colorless needle crystals.

[0074] Melting point: 247-249°C

[0075] Mass: 282 (MH + )

[0076] 1H-NMR: 2.39 (1H, s) 3.64 (2H, m) 3.76 (1H, m) 4.12 (2H, m) 5.13 (1H, t, j = 4.9) 5.51 (1H, d, j = 4.4) 5.60 ( 1H, d, j = 4.9) 6.22 (1H, d, j = 4.9) 7.10 (2H, s) 8.09 (1H, s)

[0077] In the above reaction, the corresponding nitrile was used to replace the acetonitrile as the raw material compound, and other reactions were carried out in the same manner as in Reference Example 1 to obtain the reference compound B.

[0078...

reference example 2

[0083] Synthesis of 6-methylamino-9-(β-D-arabinosfuranyl)purine [Comparative Compound C]

[0084] 1 g N 6- Methyladenosine and 1.35 g of 1,3-dichlorotetraisopropyldisiloxane were dissolved in 20 ml of pyridine and stirred at room temperature for 2 hours. After the reaction was completed, the solvent was evaporated, and the residue was separated and purified by silica gel column, and recrystallized from ethyl acetate to obtain 1.9 grams of 6-methylamino-9-[3,5,-O-(tetraisopropyldisiloxane alkane-1,3-diyl)-β-D-ribofuranyl]purine. 100 mg of this compound was dissolved in 4 ml of acetic anhydride and 10 ml of dimethylsulfoxide (DMSO), and stirred at room temperature for 16 hours. After the reaction, the solvent was distilled off and dissolved in 20 ml of L(-)-5,6,7,8-tetrahydrofolate (THF). To this solution was added 50 mg of sodium borohydride and stirred for 30 minutes. Next, 2 mL of ethanol was added and stirred for another 1 hour. After adding a small amount of acetone to...

Embodiment 1

[0088] In the reaction of reference example 2, instead of raw material compound N 6 -Methyladenosine Use the corresponding adenosine derivatives, and the others are reacted in the same way as in Reference Example 2 to obtain compounds 1 and 2. 6-methylamino-9-(β-D-arabinosylfuranyl)-2- Butylpurine [Compound 1]

[0089] Melting point: 165-166°C

[0090] Mass: 319 (MH + )

[0091] Elemental Analysis: C 15 h 23 N 5 o 4 0.2H 2 o

[0092] Theoretical value: (C, 52.98; H, 6.91; N, 20.59); measured value: (C, 52.98; H, 6.74; N, 20.76)

[0093] 1 H-NMR: 0.91 (3H, t, j=7.6) 1.35 (2H, hex, j=7.6) 1.71 (2H, qui, j=7.6) 2.67 (2H, t, j=7.6) 2.95 (3H, s) 3.64 (2H, m) 3.76 (1H, m) 4.13 (2H, m) 5.09 (1H, t, j=5.5) 5.51 (1H, d, j=4.4) 5.61 (1H, d, j=5.5) 6.24 1H, d, j = 4.4) 7.50 (1H, s) 8.06 (1H, s)

[0094] 6-Methylamino-9-(β-D-arabinosfuranyl)-2-(1-butyn-1-yl)purine [compound 2]

[0095] Melting point: 243-246°C

[0096] Mass: 334 (MH + )

[0097] Elemental Analysis: C 14 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
melting pointaaaaaaaaaa
melting pointaaaaaaaaaa
Login to View More

Abstract

An object of the present invention is to offer an Ara-A derivative having a resistance to the metabolism by ADA and also having a sufficient antiviral action. ÄConstitutionÜ A novel 2-substituted arabinosyladenine derivative represented by the formula (I) and pharmaceutically acceptable salts and hydrates thereof. <CHEM> ÄIn the formula, Z is alkyl having more than 4 carbon atoms, alkenyl or alkynyl and R is hydrogen or lower alkyl.Ü ÄMeritÜ The compounds of the present invention are Ara-A derivatives having a resistance to the metabolism by ADA and having a sufficient antiviral action whereby the problems in the prior art have been solved. The compounds of the present invention are useful as therapeutic or preventive agents for diseases infected by DNA virus such as herpes simplex virus (HSV), herpes zoster virus, cytomegalovirus (CMV), adenovirus, hepatitis virus or vaccinia virus. As compared with Ara-A, they not only show a good behavior in blood with an excellent sustaining property but also are capable of being orally administered whereby their usefulness is very high.

Description

technical field [0001] The present invention relates to 2-substituted arabinose adenine derivatives resistant to metabolic pathways caused by adenosine deaminase and their medical applications. Background technique [0002] Arabinose adenine (common name: vidarabine, hereinafter referred to as Ara-A) is effective against DNA viruses such as herpes simplex virus, herpes zoster virus, cytomegalovirus, adenovirus, hepatitis virus, and vaccinia virus. Drugs for the treatment of herpes virus infection. However, because Ara-A is metabolized by adenosine deaminase (hereinafter referred to as ADA) in the blood, hypoxanthine arabinoside with weak antiviral activity is rapidly produced, so it has the disadvantage that the antiviral activity in vitro cannot reflect the clinical effect. In addition, ADA exists in large quantities in the digestive tract, and oral Ara-A is completely metabolized before absorption. Therefore, it is difficult to apply as an oral preparation, and currently...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07H19/19A61K31/70A61K31/7042A61K31/7052A61K31/7076A61P31/12A61P31/22C07D473/34C07H19/16
CPCY10S514/934C07H19/16A61P31/12A61P31/22C07D473/34
Inventor 山田敏雄山西弘一
Owner NIPPON ZOKI PHARM CO LTD